IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3627
Positioning
Market Dominance
Manufacturing
Computer Software
$12M
Suresh Venkatachari
Healthcare Triangle, Inc. focuses on developing solutions in the sectors of cloud services, data science, and professional and managed services. It provides a suite of software, solutions, platforms, and services that enables healthcare and pharma organizations to deliver personalized healthcare. The company primarily serves healthcare delivery organizations, healthcare insurance companies, pharmaceutical and life sciences, biotech companies, and medical device manufacturers.
Headcount
80
HQ Base
Pending Verification
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$HCTI Healthcare Triangle, Inc. | 39 | 29 | 14 | 52 | - | - | -71.3% | -45.0% | 7237.3% | -49.6% | -47.7% | 16.9% | 0.0% | 59.0x | $12M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Healthcare Triangle, Inc. (HCTI) receives a "Avoid" rating with a composite score of 39.3/100. It ranks #3627 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Suresh Venkatachari
Chief Executive Officer
Labor Force
80
29
19
25
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for HCTI
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for HCTI.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
ROE proxy -71.3% (sector -2.5%)
GM 7237% vs sector 43%, OM -50% vs sector 1%
Capital turnover N/A, R&D intensity 2.4%
Rev growth 17%, 5yr history
Interest coverage -81.0x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags Healthcare Triangle, Inc. with an Avoid rating, assigning a composite score of 39.3/100 and 1 out of 5 stars. Ranked #3627 of 7,333 stocks, HCTI falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
HCTI's quality score of 29/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -71.3% (sector avg: -2.5%), gross margins of 7237.3% (sector avg: 42.5%), net margins of -47.7% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
HCTI registers a value score of just 14/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 0.12x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Healthcare Triangle, Inc.'s investment score of 19/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 16.9% vs. a sector average of 5.9% and a return on assets of -45.0% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
HCTI demonstrates moderate momentum with a score of 52/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 16.9% year-over-year, while a beta of -72.28 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
HCTI's stability score of 25/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of -72.28 and a debt-to-equity ratio of 59.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
The short interest score of 49/100 for HCTI suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 59.00x), micro-cap liquidity risk. With a $12M market cap (micro-cap), Healthcare Triangle, Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
Healthcare Triangle, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3627 of 7,333 overall (51st percentile). Key comparisons include ROE of -71.3% trailing the -2.5% sector median and operating margins of -49.6% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While HCTI currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (14) would have the largest impact on the composite score.
ROE 2776% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 16929% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 3948% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Healthcare Triangle, Inc. (HCTI) as Avoid with a composite score of 39.3/100 at a current price of $5.61. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in momentum (52th percentile) and quality (29th percentile), which together account for the majority of the composite score. Offsetting weakness in value (14th percentile) and investment (19th percentile) tempers our overall conviction. We assign a No Moat rating (26/100), High uncertainty, and Poor capital allocation.
Key items to watch: the path to profitability; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Healthcare Triangle, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 39.3/100 places it at rank #3627 in our full 7,333-stock universe. At $12M in market capitalization, Healthcare Triangle, Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 17%, though momentum at the 52th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 7237% (+7194.8pp vs sector) narrow to operating margins of -50% (-50.9pp vs sector) and net margins of -47.7%, yielding a gross-to-net conversion rate of -1%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $5.61, Healthcare Triangle, Inc. is trading at a premium to fundamental value. Our value factor score of 14/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 0.1x, P/S of 0.1x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 7237% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Revenue growth of 17% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
The Avoid rating (composite 39.3/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Thin net margins of -47.7% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Below-average quality (29th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
We assign a High uncertainty rating to Healthcare Triangle, Inc.. Key risk factors include current negative profitability (net margin -47.7%), below-average price stability (25th percentile), weak quality scores (29th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: current negative profitability (net margin -47.7%); below-average price stability (25th percentile); weak quality scores (29th percentile); low beta of -72.28 — while defensive, this may indicate limited upside participation in bull markets. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 25th percentile and quality factor at the 29th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 7237% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate Healthcare Triangle, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-71.3%), negative profitability, weak asset returns (ROA -45.0%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Healthcare Triangle, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Healthcare Triangle, Inc. receives a Avoid rating with a composite score of 39.3/100 (rank #3627 of 7,333). Our quantitative framework assigns a No Moat (26/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 28/100.
Our analysis does not support a constructive view on Healthcare Triangle, Inc. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Healthcare Triangle, Inc. a meaningful economic moat, scoring 26/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 8/20.
The strongest moat sources are margin superiority (8/20) and financial resilience (7.4/20). GM 7237% vs sector 43%, OM -50% vs sector 1%. Interest coverage -81.0x. These pillars form the core of Healthcare Triangle, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0.8/20) and economic value creation (2.5/20). Capital turnover N/A, R&D intensity 2.4%. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Healthcare Triangle, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 7237% providing a solid profitability foundation, robust top-line growth of 17% expanding the revenue base. The margin cascade from 7237% gross to -50% operating to -47.7% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 29th percentile.
The margin profile shows gross margins of 7237%, operating margins of -50%, net margins of -47.7%. Return metrics include ROE of -71.3% and ROA of -45.0%. Relative to the Manufacturing sector, gross margins are 7194.8 percentage points above the sector median of 43%, and ROE of -71.3% compares to a sector median of -2.5%.
The balance sheet reflects moderate leverage with D/E of 59%, revenue growth of 17%. The sector median D/E is 0%, putting Healthcare Triangle, Inc. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions including managed services, cloud enablement, and data analytics for the healthcare and life sciences industry, today announced that it will effect a 1-for-60 reverse stock split of its common stock. The reverse stock split will become effective at 12:01 a.m. Eastern Time on Tuesday, February 10, 2026, and the Company's common stock will commence trading on the Nasdaq Capital Market o
Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions including managed services, cloud enablement, and data analytics for the healthcare and life sciences industries, today announced that its subsidiary QuantumNexis is participating a Joint Venture with Golden Code Holdings to address the 70 Billion US dollar Healthcare Market by 2030 and align with the Saudi Arabian Kingdom's rapidly advancing healthcare transformation agenda.
Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions including managed services, cloud enablement, and data analytics for the healthcare and life sciences industries, today announced that it has entered into a Development Program Agreement with Better (www.better.care), a leading global digital healthcare platform provider. This collaboration marks a significant milestone for HCTI and its subsidiary QuantumNexis' mission to advance digi
Healthcare Triangle Inc. (NASDAQ:HCTI) shares surged 34.34% in after-hours trading to $0.40 following the completion of a $50 million acquisition of two Spanish companies, Teyamé 360 S.L. and Datono Mediación S.L., through its subsidiary Teyame AI Holdings Inc. The deal includes $12 million in restricted common stock, $18 million in convertible preferred stock, and up to $5 million in earnout payments tied to revenue and EBITDA targets through 2027.
Healthcare Triangle, Inc. (NASDAQ: HCTI) has signed a definitive agreement to acquire Teyame 360 SL and Datono Mediacion SL, Spain-based AI-powered customer experience solution providers, for approximately $50 million. The acquisition is expected to generate $38M in incremental NTM revenue and $5M in incremental NTM EBITDA, while expanding the company's SaaS footprint into Europe and Latin America. The transaction is anticipated to close on January 29, 2026, subject to shareholder approval.